Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan
Autor: | Shih-Jen Chen, Wen-Lu Chen, Fenq-Lih Lee, Cheng-Kuo Cheng, Sheng Min Hsu, Lee-Jen Chen, Chi-Chun Lai, San-Ni Chen, Ling Yeung, Chien-Hsiung Lai, Chang-Hao Yang, Tsung-Tien Wu, Chung-May Yang, De Kuang Hwang, Jiann-Torng Chen |
---|---|
Rok vydání: | 2020 |
Předmět: |
Vascular Endothelial Growth Factor A
medicine.medical_specialty Consensus Visual acuity Fundus Oculi Taiwan Visual Acuity Angiogenesis Inhibitors Disease Fundus (eye) complex mixtures Macular Degeneration Polyps Health care medicine Humans Fluorescein Angiography Intensive care medicine lcsh:R5-920 business.industry Disease Management Choroid Diseases General Medicine Macular degeneration medicine.disease eye diseases Clinical trial Choroidal neovascularization Photochemotherapy National health insurance Intravitreal Injections medicine.symptom lcsh:Medicine (General) business Tomography Optical Coherence |
Zdroj: | Journal of the Formosan Medical Association, Vol 119, Iss 2, Pp 569-576 (2020) |
ISSN: | 0929-6646 |
Popis: | Polypoidal choroidal vasculopathy (PCV) is a prevalent retinal disease predominantly occurs in Asians that shares some similarities seen in neovascular age-related macular degeneration. Recent large multicenter clinical trials on intravitreal anti-vascular endothelial growth factor (VEGF) agents and photodynamic therapy (PDT) have shed lights on the management of PCV. The Taiwan National Health Insurance had granted limited anti-VEGF agents and PDT for patients with PCV after the approval of required data submission, especially fundus angiography, optical coherence tomography, and visual acuity. In order to best utilize these limited resources for the patients, an expert meeting was held to provide updated Taiwan consensus recommendations for the management of PCV, including initial therapy selection, assessment of treatment response, re-treatment/rescue treatment, and determination of treatment extension/follow-up schedule. An algorithm for treatment allocation under both initial and re-treatment setting was proposed. Further mechanistic and clinical studies are required to investigate the prognostic factors and optimal treatment protocols that will improve healthcare quality and reduce burden of disease and treatment for patients with PCV. Keywords: Choroidal neovascularization, PCV, Photodynamic therapy, Vascular endothelial growth factors, Wet age-related macular degeneration |
Databáze: | OpenAIRE |
Externí odkaz: |